Skip to main content

Angeles Alvarez Secord, MD

Angeles Secord, MD
Professor of Obstetrics and Gynecology
Campus Mail: 25172 Morris Bldg, Durham, NC 27710
Phone: (919) 684-3765
Email: secor002@mc.duke.edu

My primary research interest has focused on angiogenesis, molecular signatures, clinical trial development, and ovarian cancer. My fundamental goal is to develop a strong translational research program at Duke University in the Gynecologic Oncology Division where knowledge we glean from our basic science research can be incorporated into our clinical trial program. Specifically on anti-angiogenic therapy and molecular tumor signatures to direct therapy in patients with ovarian cancer to determine if a strategy that incorporates both clinical and genomic information can improve clinical outcome, minimize unnecessary toxicity, and impact positively on quality of life.
In addition I am interested in robotic-assisted laparoscopic surgery for women with endometrial, ovarian, and cervical cancers as well as for benign gynecologic conditions.

Education and Training

  • Resident, Obstetrics & Gynecology, Duke University, 1994 - 1998
  • M.D., University of Washington, 1994

Certifications

  • Duke University Medical Center, Masters of Health Sciences in Clinical Research, 2005-2011

Research

Dr. Secord's research interests include elucidating the underlying genetic biology of angiogenesis in ovarian cancer, innovative clinical trial design, development of novel targeted therapies for personalized medicine, identification of biomarkers to direct anti-neoplastic therapy, and the incorporation of patient-reported outcomes in clinical trials. She has studied the regulation of angiogenesis in ovarian cancer for approximately 20 years and has recently extended our research to include the immunophenotype of the tumor microenvironment. 

 

Selected Grants and Awards

Publications

Moore, K, Chan, JK, Secord, AA, Patel, MR, Callahan, T, Guo, W, and Zhang, Z-Y. "Effect of niraparib on cardiac repolarization in patients with platinum-sensitive, recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer.(Accepted)" Cancer Chemotherapy and Pharmacology 83, no. 4 (April 2019): 717-726.

Full Text

Previs, RA, and Secord, AA. "Ovarian Cancer: Clinical Trial Breakthroughs and Impact on Management." Obstetrics and Gynecology Clinics of North America 46, no. 1 (March 2019): 67-88. (Review)

Full Text

Foote, JR, Secord, AA, Liang, MI, Ehrisman, JA, Cohn, DE, Jewell, E, and Havrilesky, LJ. "Targeted composite value-based endpoints in platinum-sensitive recurrent ovarian cancer." Gynecologic Oncology 152, no. 3 (March 1, 2019): 445-451.

Full Text

Lim, SL, Havrilesky, LJ, Habib, AS, and Secord, AA. "Cost-effectiveness of hyperthermic intraperitoneal chemotherapy (HIPEC) at interval debulking of epithelial ovarian cancer following neoadjuvant chemotherapy." Gynecologic Oncology (February 2019).

Full Text

Rose, PG, Java, JJ, Salani, R, Geller, MA, Secord, AA, Tewari, KS, Bender, DP, Mutch, DG, Friedlander, ML, Van Le, L, Method, MW, Hamilton, CA, Lee, RB, Wenham, RM, Guntupalli, SR, Markman, M, Muggia, FM, Armstrong, DK, Bookman, MA, Burger, RA, and Copeland, LJ. "Nomogram for Predicting Individual Survival After Recurrence of Advanced-Stage, High-Grade Ovarian Carcinoma." Obstetrics and Gynecology 133, no. 2 (February 2019): 245-254.

Full Text

Puechl, AM, Edwards, J, Suri, A, Nakayama, J, Bean, S, Gehrig, P, Saks, E, Duska, L, Broadwater, G, Ehrisman, J, Horowitz, N, and Secord, AA. "The association between progesterone receptor expression and survival in women with adult granulosa cell tumors." Gynecologic Oncology (January 17, 2019).

Full Text

Davidson, BA, Broadwater, G, Crim, A, Boccacio, R, Bixel, K, Backes, F, Previs, RA, Salinaro, J, Salani, R, Moore, K, and Secord, AA. "Surgical complexity score and role of laparoscopy in women with advanced ovarian cancer treated with neoadjuvant chemotherapy." Gynecologic Oncology (December 14, 2018).

Full Text

Monk, BJ, Kauderer, JT, Moxley, KM, Bonebrake, AJ, Dewdney, SB, Secord, AA, Ueland, FR, Johnston, CM, and Aghajanian, C. "A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study." Gynecologic Oncology 151, no. 3 (December 2018): 422-427.

Full Text

Lim, SL, Moss, HA, Secord, AA, Lee, PS, Havrilesky, LJ, and Davidson, BA. "Hysterectomy with sentinel lymph node biopsy in the setting of pre-operative diagnosis of endometrial intraepithelial neoplasia: A cost-effectiveness analysis." Gynecologic Oncology 151, no. 3 (December 2018): 506-512.

Full Text

Tew, WP, Sill, MW, Walker, JL, Secord, AA, Bonebrake, AJ, Schilder, JM, Stuckey, A, Rice, L, Tewari, KS, and Aghajanian, CA. "Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study." Gynecologic Oncology 151, no. 2 (November 2018): 257-263.

Full Text

Pages